Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

Beckman Coulter awarded new agreement with Premier Purchasing Partners for laboratory systems and supplies

Beckman Coulter, Inc., a leading developer, manufacturer, and marketer of products that simplify, automate, and innovate complex biomedical testing, announced that effective April 1, 2010, it has been awarded a new agreement with Premier Purchasing Partners, the group purchasing unit of Premier, Inc., to provide a full range of core laboratory systems and supplies. Premier is one of the nation's largest healthcare purchasing networks, with more than 2,300 member hospitals and 64,000 additional healthcare sites.

From Beckman Coulter Diagnostics 15 Apr 2010

Implementation of electronic health record systems may not be enough to improve health quality

The implementation of electronic health record systems may not be enough to significantly improve health quality and reduce costs. In the April 2010 issue of Health Affairs, researchers from the Mongan Institute for Health Policy at Massachusetts General Hospital report finding that currently implemented systems have little effect on measures such as patient mortality, surgical complications, length of stay and costs.

7 Apr 2010

AHRQ: Women accounted for nearly 60% of 39.4M admissions to U.S. hospitals in 2007

Women accounted for nearly 60 percent of the 39.4 million admissions to U.S. hospitals in 2007, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

7 Apr 2010

Rebirth of the cursed drug Thalidomide

Thalidomide was once a dreaded name in the Pharmaceutical industry. It was initially marketed in some European countries nearly 5 decades back as a sedative and after millions of pregnant women took it for morning sickness it had devastating results on the babies. The babies were born with flippers instead of limbs a condition known as phocomelia. Since then it has been under strict control.

5 Apr 2010

Study shows imaging technique useful for planning cardiac procedures

For a patient with heart failure, checking whether the heart could benefit from bypass surgery or a stent is critical to ensuring survival. One imaging technique, positron emission tomography (PET) with the imaging agent fluorodeoxyglucose (FDG), may provide doctors with the information they need to make more informed treatment decisions, according to research published in the April issue of The Journal of Nuclear Medicine (JNM).

2 Apr 2010

Bioheart presents cutting edge therapies at 2010 Translational Regenerative Medicine Forum

Bioheart, Inc., announced today that Dr. Karl E. Groth, the Company's Chairman and CEO will speak at the 2010 Translational Regenerative Medicine Forum in Winston-Salem, North Carolina, on April 8. Dr. Groth will discuss Bioheart's cell therapies for Congestive Heart Failure.

31 Mar 2010

Cardima announces CE Mark approval for Surgical Ablation Probe in Surgical Treatment of Atrial Fibrillation

Cardima, Inc., a medical device company focused on the treatment of atrial fibrillation (AF) and manufacturer of the Cardima Surgical Ablation System, today announced that it has received CE Mark approval with an Indication for the Surgical Treatment of Atrial Fibrillation for its Surgical Ablation Probe. All components of the Cardima Surgical Ablation System are now approved for marketing for the treatment of AF in European countries recognizing CE Mark approval.

29 Mar 2010

Seniors with diabetes and dementia more likely to fall into Medicare Part D prescription drug plan

Among seniors, women and patients with diabetes and dementia are the most likely to fall into the Medicare Part D prescription drug plan "donut hole" - the gap occurring after beneficiaries reach their annual coverage limit and before catastrophic coverage kicks in - according to new research published online in the Journal of General Internal Medicine.

29 Mar 2010

Medical conditions put seniors at high risk of unsubsidized medical prescription expenses

If you're older, a woman, and suffering from either dementia or diabetes, you are the most likely to be exposed to unsubsidized medication costs in the US. This is known as the coverage gap for enrollees of Medicare Part D - the US federal program which subsidizes the cost of prescription drugs for Medicare beneficiaries.

26 Mar 2010

Single-incision laparoscopy reduces postoperative complications

Surgeons at the University of California, San Diego School of Medicine report what is believed to be the nation's first single-incision laparoscopy to perform a combined colectomy and kidney-preserving therapy.

26 Mar 2010

Bioheart to open five centers to provide cell therapy procedures for congestive heart failure patients

Bioheart, Inc., announced today plans for establishing five Centers of Excellence in Latin America to provide its cell therapy procedures to patients suffering from congestive heart failure and peripheral arterial disease beginning next month, April 2010. Bioheart entered into its first agreement with a leading treatment facilitator, Regenerative Medicine Institute of Tijuana, Mexico. Therapies for CHF and PAD patients will be made available at the Hospital Angeles Tijuana, a fully equipped state-of–the-art private specialties hospital. This will be the first of five Centers of Excellence with four additional Centers to be announced in the coming months.

24 Mar 2010

$CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval$

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee panel voted unanimously that clinical trial data was not adequate to support approval of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Mar 2010

Deborah Heart and Lung Center named Top Work Places 2010 and Best Hospital in New Jersey

Not once, but three times this week, Deborah Heart and Lung Center has been recognized as one of the best places to work and receive care. In three separate competitive reviews, Deborah, a specialty heart, lung, and vascular hospital in Browns Mills, has been recognized as a top workplace and top hospital.

22 Mar 2010

Mitral regurgitation: MitraClip safe, effective alternative option to open heart surgery

NorthShore University HealthSystem (NorthShore) interventional cardiologist, Ted Feldman, MD, presented data today at the American College of Cardiology annual scientific sessions from the EVEREST II trial (Endovascular Valve Edge-to-Edge REpair STudy) demonstrating the MitraClip, a novel, first-in-class catheter-based device, is a safe and effective alternative to open heart surgery for select patients with mitral regurgitation.

15 Mar 2010

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).

15 Mar 2010

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.

12 Mar 2010

Response Biomedical's 2009 total revenues up 69%

Response Biomedical Corporation reported that it recorded total revenues of $9,946,269, an increase of 69% compared to $5,876,337 in 2008. Clinical products revenue for the year ended December 31, 2009 increased 85% to $6,828,651 compared to $3,683,706 in 2008.

11 Mar 2010

Aastrom Biosciences treats final patient in IMPACT-DCM Phase 2 surgical clinical trial

Aastrom Biosciences, Inc., a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported the final patient treatment in the company's ongoing U.S. Phase 2 surgical clinical trial designated IMPACT-DCM.

10 Mar 2010

University of Michigan Health System evaluates factors that can reduce hospital deaths

Admission to a hospital when most of the beds are already full can be deadly for patients, according to a new University of Michigan Health System study showing high occupancy increases the risk of dying in the hospital by 5.6 percent.

9 Mar 2010

In future, less invasive transcatheter heart valve replacements will benefit people with heart disease

A significant number of people with heart disease will benefit from less invasive transcatheter heart valve replacements in future, finds a review of updated practices in CMAJ.